HRD-negative high-grade carcinoma of the ovary in <i>BRCA2</i> pathogenic variant carrier
Background. Homologous recombination deficiency (HRD) is a valuable molecular marker for predicting response to platinum agents and poly(ADP-ribose)-polymerase (PARP) inhibitors. Germline and somatic alterations in the BRCA1 and BRCA2 genes are the major cause of HRD in ovarian cancer. However, in s...
Saved in:
| Main Authors: | A. P. Sokolenko, S. V. Poletaeva, A. D. Shestakova, T. V. Gorodnova, I. V. Berlev, E. N. Imyanitov |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2024-05-01
|
| Series: | Сибирский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.siboncoj.ru/jour/article/view/3050 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
LOSS OF HETEROZYGOSITY IN THE BRCA1 AND BRCA2 LOCUS IN BREAST CANCER
by: M. M. Tsyganov, et al.
Published: (2020-07-01) -
WNT inhibition creates a BRCA‐like state in Wnt‐addicted cancer
by: Amanpreet Kaur, et al.
Published: (2021-03-01) -
SMAD4 depletion enhances NHEJ by regulating BRCA1 expression through ARIH1 in pancreatic cancer
by: Yiran Song, et al.
Published: (2025-05-01) -
The Interplay Between DNA Repair and the Immune Microenvironment in Pancreatic Cancer
by: Aaron Ciner, et al.
Published: (2025-04-01) -
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
by: Marta Castroviejo‐Bermejo, et al.
Published: (2018-10-01)